CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Area of Science:

• Cardiology
• Nephrology
• Endocrinology
• Metabolic Diseases

Background:

• The 8th Cardiovascular Outcome Trial (CVOT) Summit convened experts to discuss recent trial results and their clinical implications.
• The summit focused on the DELIVER, EMPA-KIDNEY, and SURMOUNT-1 trials, examining treatments for heart failure, chronic kidney disease, and obesity.

Discussion:

• Key discussions centered on sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonists.
• Participants explored updates in type 2 diabetes (T2D) and chronic kidney disease (CKD) management, including guideline revisions and clinical inertia.
• The role of continuous glucose monitoring (CGM), novel insulins, and combination therapies were also debated.

Key Insights:

• SGLT2 inhibitors show significant promise in managing heart failure (HF) and chronic kidney disease (CKD).
• GIP and GLP-1 receptor agonists are emerging as crucial in obesity management.
• Real-world evidence (RWE) is increasingly important for validating CVOT findings and informing trial design.

Outlook:

• Future research will likely focus on optimizing the use of these agents and exploring their impact on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
• The integration of RWE and advanced monitoring techniques like CGM will shape future clinical practice and trial methodologies.
• The 9th CVOT Summit is scheduled for November 23-24, 2023, continuing the dialogue on cardiovascular, kidney, and glycemic outcomes.